Hi Adus, when assessing the risk here, a primary consideration is surely the guidelines set out by the FDA for PH3.
The fact that RSBQ is a co-primary efficacy endpoint (along with CGI-I) a scale which they have already demonstrated clear efficacy AND that the FDA have agreed to a 6 month trial indicates two things to me.
Firstly, whilst these things are never a home run the chances of success in at least one of these endpoints (and I would personally be confident of both given correct dosages) are considerably higher than average. Secondly the FDA are clearly on board with trying to get this to market as soon as possible.
You may consider this spruiking but that’s my 2 cents
Release Today Neuren Valuation Estimate Raised, page-72
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.27 |
Change
0.920(6.41%) |
Mkt cap ! $1.951B | |||
| Open | High | Low | Value | Volume |
| $14.35 | $15.27 | $14.35 | $8.720M | 579.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | $15.25 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.27 | 3638 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |